On-Demand Webinars
-
From Powder To Particles With Jet Milling
Gain valuable insights into the jet milling process and Quality by Design approach for inhalation drug delivery and their potential applications in drug development.
-
Strategies For Lipid-Based Drug Delivery Systems And Oral Dosage Forms
Experts share principles, advantages and disadvantages of different dose forms, and considerations for selecting a suitable dosage form for early phase development programs to commercialization.
-
Amorphous And Co-Amorphous Systems For Poorly Soluble Drugs
Review co-amorphous research and recent findings, particularly the impact of low molecular weight excipient on developability, stability, and solubility.
-
EU Med Device Regulations: Ensuring Compliance For Integral Combination Products
Review the EU Medical Device Regulation (MDR) changes, specifically with respect to integral combination products, and examine the technical documentation packages supporting functionality and content.
-
Increasing Spray Drying Throughput For Brick Dust Compounds
‘Brick dust’ compounds require additional steps if spray drying is to yield a commercially attractive process. Explore three enabling technologies designed to improve drug solubility in organic solvents for spray drying.
-
HPAPI Drug Product Development And Manufacturing Using Micronization Technology
Learn how to classify HPAPIs in early development and recommendations for safe product handling, from clinical manufacturing to commercialization.
-
Key Considerations When Developing Your Combination Product
2/20/2024
Succeed in combination product development by understanding the risk factors that may arise and implementing mitigation strategies that will streamline the device development process.
-
Regulatory, Cost Implications Of Switching Injectable Delivery Formats
Launching a large molecule in one format and then switching the delivery format often transpires as a lifecycle management strategy for cost efficiency, supply chain continuity, and patient benefit.
-
Elemental Impurities Risk Assessment For Finished Drug Products
Review the impact of regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.
-
Nanoforming: The Patient- And Planet-Centric Approach
By reducing the size of drug particles, nanoforming can open up new opportunities – from increasing bioavailability to enabling sustained drug delivery. Discover the potential benefits supported by case studies.